<p>Alzheimer’s disease (AD) continues to plague the healthcare community as a serious healthcare crisis. Currently there fails to be an effective FDA approved drug that can treat the underlying mechanisms of the disease. Pathologically the disease is characterized by the accumulation of neurotoxic amyloid-b(Ab) plaques within a diseased patient’s brain. These plaques are widely accepted to be generated by the sequential proteolytic cleavage of amyloid precursor protein (APP) by b-secretase (BACE1, memapsin 2) and g-secretase. Numerous biochemical markers suggest that BACE1 is a viable target for AD drug development. Since the cloning and expression of BACE1 there has been an explosion of drug development efforts that have consisted of peptidomimetic-based and non-peptide-based inhibitors. These efforts have led to 13 BACE1 drug candidates some of which have made it to advanced stages of clinical trials. Unfortunately, an effective and tolerable BACE1 drug candidate continues to be rather elusive to the medicinal chemistry community. GRL-8234 is a potent BACE1 inhibitor that has been extensively shown to be tolerable during several short-term and long-term <i>in vivo </i>studies. The scaffold of GRL-8234 provides a suitable template for further lead development. Namely the P1’ 3-methoxy-benzylamine is of particular interest due to the advantageous interactions in the flap region of BACE1 that can be achieved by incorporation of substitution at the benzylic position. In the same way, the <i>meta</i>-substituent of the benzylamine P1’ ligand was investigated to probe the hydrophobic interactions in the S1’-S2’ binding pocket. A novel class of BACE1 inhibitors containing P1’ spirocyclic benzylamine derivatives were designed, synthesized and evaluated for their inhibitory activity against BACE1. In the process of preparing the aforementioned BACE1 inhibitors a method was established to be able to incorporate the desired 3,5-difluorophenyl methyl transition state isostere by utilizing an ester-derived Ti-enolate to access optically pure <i>syn</i>- and <i>anti</i>-aldol adducts as a key step. Additionally, a novel stereoselective method was established to afford heterospirocyclic benzylamines by utilizing a diastereoselective allyl grignard addition to optically pure a-silyloxy <i>N</i>-sulfinyl ketimines as a key step. Biological evaluation of these novel BACE1 inhibitors has been fruitful and continues to be ongoing. </p>

<p>In 2018, the World Health Organization (WHO) reported approximately 37 million people are living with the Human Immunodeficiency Virus (HIV). Suppressing replication of the virus down to undetectable levels was achieved by combination antiretroviral therapy (cART) which effectively reduced the mortality and morbidity rates of HIV positive individuals. Despite the improvements towards combatting HIV/AIDS, no successful treatment exists to eradicate the virus from an infected individual. Treatment regimens are lifelong and prompt less than desirable side effects including but not limited to; drug-drug interactions, toxicity, systemic organ complications, central nervous system HIV triggered disorders and most importantly, drug resistance. Current therapies are becoming ineffective against highly resistant HIV strains making the ability to treat long-term viral suppression a growing issue. Therefore, potent and more effective HIV inhibitors provide the best chance for long-term successful cART. </p> <p>HIV-1 protease (PR) enzyme plays a critical role in the life cycle and replication of HIV. Significant advancements were achieved through structure-based design and X-ray crystallographic analysis of protease-bound to HIV-1 and brought about several FDA protease inhibitors (PI). Highly mutated HIV-1 variants create a challenge for current and future treatment regimens. This thesis work focuses on the design, synthesis, and evaluation of two new classes of potent HIV-1 PIs that exhibit a novel bicyclic oxazolidinone feature as the P2 ligand and a novel bis squaramide scaffold as the P2/P3 ligand. Several inhibitors displayed good to excellent activity toward HIV-1 protease and significant antiviral activity in MT-4 cells. Inhibitors 1.65g and 1.65h were further evaluated against a panel of highly resistant multidrug-resistant HIV-1 variants and displayed antiviral activity similar to Darunavir. X-ray crystal structures of inhibitor 1.65a and inhibitor 1.65i were co-crystallized with wild type HIV-1 protease and solved at a 1.22 Å and 1.30 Å resolution and maintained strong hydrogen bond with the backbone of the PR enzyme. </p>

Chronic ulcers are an important and costly medical issue, causing their sufferers a large amount of pain, immobility and decreased quality of life. The common pathology in these chronic wounds is often characterised by excessive proteolytic activity, leading to the degradation of both the extracellular matrix, as well as key factors critical to the ulcer's ability to heal. As matrix metalloproteinases (MMPs), a large family of zinc-dependent endopeptidases, have been shown to have increased activity in chronic wound fluid (CWF), it was hypothesised that this specific proteolytic activity was directly related to an ulcer's chronic nature. Although previous studies have identified elevated proteases in CWF, many have reported contradictory results and therefore the precise levels and species of MMPs in CWF are poorly understood. The studies reported herein demonstrate that MMP activity is significantly elevated in CWF compared with acute wound fluid (AWF). In particular, these studies demonstrate that this proteolytic activity can be specifically attributed to MMPs and not another class of proteases present in wound healing. Furthermore, it is shown that MMP-9 is the predominant protease responsible for matrix degradation by CWF and is an indicator of the clinical status of the wound itself. Moreover, MMP-9 can be inhibited with the bisphosphonate alendronate, in the form of a sodium salt, a functionalised analogue, and also tethered to a synthetic biocompatible hydrogel compromised of aqueous poly (2-hydroxy methacrylate) PHEMA synthesised in the presence of poly(ethylene glycol) (PEG). Together, these results highlight the potential use of a tethered MMP inhibitor as an improved ulcer treatment to inhibit protease activity in the wound fluid, while still allowing MMPs to remain active in the wound bed where they perform vital roles in the activation of growth-promoting agents and immune system regulation.

No description available.

A presença de inibidores no plasma e soro de animais resistentes ao veneno de serpentes, assim como no plasma ou soro de serpentes imunes a seu próprio veneno, é amplamente conhecida. Um grupo destes inibidores são os inibidores de metaloproteases do veneno de serpente (SVMPs), eles têm sido caracterizados do ponto de vista físico químico, porém a falta de informações estruturais e termodinâmicas acerca da sua inibição sobre as SVMPs, tem permanecido como um grande obstáculo para sua aplicação terapêutica ou desenvolvimento como ferramentas moleculares. Por tanto, isolamos um novo inibidor de metaloproteases a partir do soro de C. d. terrificus, por nós denominado crotaini, e realizamos a caracterização cinética de sua interação com a bothropasina, uma das principais metaloproteases do veneno de B. jararaca, e da mesma forma, caracterizamos cineticamente a interação desta metaloprotease com dos inibidores já conhecidos, DM40 e DM43, isolados do soro de D. marsupialis. Determinando as constantes cinéticas mediante cinética enzimática e ressonância plasmônica de superfície (SPR) no Biacore T200. Os valores obtidos permitiram estabelecer que a interação entre o crotaini e a bothropasina, é de alta afinidade, além de evidenciar a sua ligação de forma equimolar e estável. Assim mesmo, o crotaini apresentou uma constante de inibição menor às constantes determinadas para o DM40 e DM43. Adicionalmente, estudos de interação após tratamento quelante da enzima permitem prever que existem diferenças respeito aos domínios estruturais envolvidos na interação do crotaini com a bothropasina, em comparação aos inibidores DM40 e DM43. / The presence of inhibitors in plasma or serum from snake venom - resistant animals is well known. These inhibitors are also present in plasma and serum of snakes that are immune to their own venom. A group of these molecules are snake venom metalloprotease inhibitors (SVMPIs). Although the physicochemical properties of these inhibitors are well established, the lack of structural and thermodynamic information has been a bottleneck for their therapeutic use and development as molecular tools. In this work a new metalloprotease inhibitor was isolated from C. d. terrificus, and named crotaini. The kinetic interaction of crotaini with bothropasin, one of the main metalloproteases from the B. jararaca venom, was investigated. Similarly, the kinetic interactions of crotaini with the inhibitors DM40 and DM43, isolated from D. marsupialis serum, were also studied. The kinetic constants were determined by enzymatic kinetics and surface plasmonic resonance (SPR) in a Biacore T200. The obtained values enabled us to demonstrate the high affinity of the inhibitors toward the metalloprotease, achieved through an equimolar and stable complex formation. In addition, studies of interactions of the metaloprotease bothropasin with its inhibitors in the presence of chelant agents revealed differences between that established with crotaini as compared with those made with DM40 and DM43.